Advertisement
Advertisement
U.S. markets close in 5 hours 48 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Valeo Pharma Inc. (VPH.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.61000.0000 (0.00%)
As of 03:56PM EDT. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6100
Open0.6300
Bid0.6100 x N/A
Ask0.6300 x N/A
Day's Range0.6100 - 0.6300
52 Week Range0.4500 - 0.9700
Volume25,938
Avg. Volume45,918
Market Cap49.806M
Beta (5Y Monthly)2.56
PE Ratio (TTM)N/A
EPS (TTM)-0.2800
Earnings DateSep 20, 2022 - Sep 26, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.63
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for VPH.TO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • CNW Group

      VALEO PHARMA CLOSES US$40 MILLION NON-DILUTIVE FINANCING FROM SAGARD HEALTHCARE PARTNERS

      Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a growing Canadian pharmaceutical company, is pleased to announce that, it has closed a non-dilutive US$40 million Secured Term Loan (the "Facility") from Sagard Healthcare Partners.

    • CNW Group

      VALEO PHARMA ENTERS INTO LICENSE AGREEMENT WITH KALÉO FOR THE CANADIAN RIGHTS TO ALLERJECT®

      Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a growing Canadian pharmaceutical company, announced today that it has entered into a License, Supply, and Commercialization agreement with Kaléo Inc. for the Canadian rights to ALLERJECT, (epinephrine injection, USP) auto-injector for the treatment of serious allergic reactions.

    • CNW Group

      VALEO PHARMA ENTERS INTO AN AGREEMENT FOR OPHTHALMIC PRODUCTS, PrXIIDRA® AND PrSIMBRINZA®, IN CANADA

      Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it has entered into a Commercialization and Supply Agreement (the "Agreement") with Novartis Pharmaceuticals Canada Inc. ("Novartis") for the Canadian commercialization by Valeo of two innovative ophthalmic therapies. Under the Agreement, Valeo becomes the exclusive distributor of XIIDRA® (lifitegrast) and SIMBRINZA® (brinzolamide / brimonidine tartrate) in C

    Advertisement
    Advertisement